Skip to main content
TYK Medicines, Inc logo

TYK Medicines, Inc — Investor Relations & Filings

Ticker · 2410 ISIN · CNE100006L34 HKEX Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2025-05-16 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 2410

About TYK Medicines, Inc

https://www.tykmedicines.com

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule targeted therapies. The company leverages a proprietary small molecule drug design and screening platform, with a primary strategic focus on oncology, particularly treatments for lung cancer. The lead pipeline asset, TY-9591 (Edotamidine mesylate), an EGFR-targeted therapy, is currently in the Pre-NDA stage, having demonstrated promising clinical efficacy in treating lung cancer patients with brain metastasis. The pipeline also includes assets such as TY-302 and TY-2136, alongside multiple CDK inhibitors in clinical development, reflecting a commitment to addressing unmet medical needs in targeted cancer treatment.

Recent filings

Filing Released Lang Actions
PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 95% confidence The document is a corporate announcement regarding the proposed appointment of a new non-executive director, detailing his biography, appointment terms, and conditions pending shareholder approval at the forthcoming AGM. This constitutes an announcement of a board-level management change. Therefore, it falls under Board/Management Information (MANG).
2025-05-16 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2025
Regulatory Filings Classification · 72% confidence The document is a routine monthly return filed to Hong Kong Exchanges and Clearing Limited under Chapter 19B of the Listing Rules, reporting movements in registered share capital and issued shares. It is not an announcement of a specific transaction (e.g., share issue, buyback), not a management discussion or AGM material, but a regulatory compliance submission. There is no substantive change or press release style; it is a compliance report that doesn’t fit other specific categories. Therefore, it falls under Regulatory Filings (RNS).
2025-05-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
Regulatory Filings Classification · 85% confidence The document is titled “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities” and details authorized/issued share capital movements for a Hong Kong–listed company filed with HKEX. It is a recurring regulatory form submission rather than a corporate earnings release, management discussion, or other specific report type. This fits the fallback category for general regulatory announcements/filings. Therefore, it should be classified as a Regulatory Filing (RNS).
2025-05-02 English
Annual Report 2024
Annual Report Classification · 100% confidence The document is explicitly titled '2024 ANNUAL REPORT' and contains standard sections such as 'Chairman's Statement', 'Financial Highlights', 'Business Highlights', 'Management Discussion and Analysis', and 'Independent Auditor's Report'. It covers the company's full-year performance, financial statements, and operational updates for the fiscal year 2024. It is a comprehensive annual report, not an announcement or a summary. FY 2024
2025-04-29 English
UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2025
Earnings Release Classification · 85% confidence The document is an unaudited financial announcement of the Group’s results for the three months ended 31 March 2025. It contains financial highlights (revenue, loss, assets, equity), operational commentary, and a caution statement, but does not present full statutory financial statements. This matches an initial earnings announcement of quarterly results (key highlights only), rather than a full interim/quarterly report. Therefore, it should be classified as an Earnings Release (ER). Q1 2025
2025-04-25 English
CONNECTED TRANSACTION - PARTICIPATION IN ESTABLISHMENT OF FUND
Regulatory Filings Classification · 68% confidence The document is a formal announcement relating to a connected transaction under the Hong Kong Listing Rules (Chapter 14A). It details the Company’s participation in the establishment of a joint venture fund, capital commitment, governance, and regulatory disclosures. It is not a financial report (Annual, Interim, or Earnings), nor a vote result, management change, or share issuance. There is no indication of an earnings call transcript, investor presentation, or proxy materials. It is a regulatory announcement about a corporate transaction that does not fit other specific categories, hence it defaults to a general regulatory filing (RNS).
2025-04-24 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.